CN Patent

CN106905250A — 一种雷西纳德的新晶型

Assigned to Jiangsu Ai Kang Pharmaceutical Ltd By Share Ltd · Expires 2017-06-30 · 9y expired

What this patent protects

本发明提供了一种雷西纳德的新晶型，为多晶型形式3，所述多晶型形式3其粉末X‑射线衍射图在大约 4.31、8.57、18.50、20.08、21.75、23.91、25.80 2θ±0.2°处有衍射峰。该晶型具备良好的化学稳定性和晶型纯度，易于制备，操作简单，能更好地适用于制备药物制剂和规模化生产，应用前景广阔。

USPTO Abstract

本发明提供了一种雷西纳德的新晶型，为多晶型形式3，所述多晶型形式3其粉末X‑射线衍射图在大约 4.31、8.57、18.50、20.08、21.75、23.91、25.80 2θ±0.2°处有衍射峰。该晶型具备良好的化学稳定性和晶型纯度，易于制备，操作简单，能更好地适用于制备药物制剂和规模化生产，应用前景广阔。

Drugs covered by this patent

Patent Metadata

Patent number
CN106905250A
Jurisdiction
CN
Classification
—
Expires
2017-06-30
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Ai Kang Pharmaceutical Ltd By Share Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.